Journal
CANCER INVESTIGATION
Volume 26, Issue 6, Pages 624-633Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07357900802027073
Keywords
melanoma; chemotherapy; biochemotherapy; interleukin-2; survival
Categories
Ask authors/readers for more resources
This retrospective analysis aimed to identify the prognostic factors that influenced long-term survival of patients with metastatic melanoma. The medical records for 616 chemo-naive patients who were treated with systemic therapy on eight phase II/III clinical trials were reviewed. Clinical characteristics, disease stage, metastatic sites, baseline serum albumin, LDH, and response to treatment were compared between the treatment groups and significant prognostic factors were identified. Cox proportional-hazards regression analysis identified treatment with biochemotherapy, younger age, normal baseline serum albumin and LDH levels, ECOG P.S. < 2 and absence of visceral metastasis as favorable prognostic factors for long-term survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available